Μετάβαση στο περιεχόμενο

ΕτικέταAlnylam

Alnylam Receives FDA Approval for First-Ever RNA Interference Therapeutic

The U.S. Food and Drug Administration (FDA) approved Alnylam Pharmaceuticals’ Onpattro (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. It is the first and only RNA interference (RNAi) therapeutic … Continue Reading Alnylam Receives FDA Approval for First-Ever RNA Interference Therapeutic